Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Observatory
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Signals Session
  • Bespoke Projects
  • Build Sessions
  • Use Cases
  • Readinessfree
  • Signals
  • Free scan↗free
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
solutions
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Partners
  • Coding for Non-Coders
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
ResearchServicesSignalsAbout
ResearchServicesSignalsAbout
  1. Home
  2. Research
  3. Helix
  4. 3D-Bioprinted Vascularized Tissue Constructs

3D-Bioprinted Vascularized Tissue Constructs

Printers capable of generating functional capillary networks within lab-grown organs.
Back to HelixView interactive version

3D-bioprinted vascularized tissue constructs use advanced bioprinters that can simultaneously deposit living cells and sacrificial materials (inks that are later removed) to create intricate, patent vascular networks within engineered tissues. This hardware breakthrough solves the fundamental diffusion limit problem in tissue engineering, where cells more than a few hundred micrometers from a blood supply cannot survive due to oxygen and nutrient limitations. By creating functional capillary networks, these systems enable the creation of thick, viable tissue grafts and pave the way for fully functional lab-grown organ replacements.

This innovation addresses the critical challenge in tissue engineering where creating large, thick tissues has been impossible without vascularization. Traditional tissue engineering approaches could only create thin layers of cells, limiting applications. By enabling vascularization, bioprinting can create tissues of meaningful size and complexity. Companies like Organovo, 3D Bioprinting Solutions, and research institutions are developing these capabilities.

The technology is essential for advancing toward functional organ replacement, where creating tissues with integrated blood supply is a fundamental requirement. As the technology improves, it could enable the creation of transplantable organs, addressing the critical shortage of donor organs. However, creating functional, long-lasting vascular networks, ensuring proper integration with host vasculature, and scaling to full-size organs remain significant challenges. The technology represents a major advance in tissue engineering capabilities, but requires continued development to achieve the complexity and functionality needed for organ replacement. Success could transform transplantation medicine by providing an unlimited supply of compatible organs, but the path from current capabilities to functional organ replacement is long and requires many additional advances.

TRL
4/9Formative
Impact
5/5
Investment
4/5
Category
Hardware

Related Organizations

Prellis Biologics

United States · Startup

95%

Specializes in holographic laser printing to create vascularized tissue scaffolds at high speed.

Developer
Tel Aviv University (Tal Dvir Lab)

Israel · University

95%

Research lab that successfully 3D printed a vascularized engineered heart using a patient's own cells.

Researcher
Volumetric

United States · Company

95%

Developed the 'Print to Perfusion' technology for creating vascularized tissues; acquired by 3D Systems.

Developer
Wyss Institute for Biologically Inspired Engineering logo
Wyss Institute for Biologically Inspired Engineering

United States · Research Lab

95%

Developed the SWIFT (Sacrificial Writing into Functional Tissue) method for 3D printing vascular channels in living matrices.

Researcher
Aspect Biosystems logo
Aspect Biosystems

Canada · Company

90%

Uses microfluidic 3D bioprinting technology to create bioprinted therapeutics, partnering with Novo Nordisk.

Developer
Fluicell

Sweden · Company

85%

Provides single-cell bioprinting platforms (Biopixlar) capable of creating detailed tissue microenvironments.

Developer
Poietis logo

Poietis

France · Company

85%

Uses laser-assisted bioprinting (LAB) to print living cells with single-cell resolution.

Developer
Advanced Solutions Life Sciences

United States · Company

80%

Creators of the BioAssemblyBot, a robotic arm bioprinter capable of complex vascular workflows.

Developer

Supporting Evidence

Evidence data is not available for this technology yet.

Research this in Signals

Scan 3D-Bioprinted Vascularized Tissue Constructs for yourself.

Signals turns a topic into a sourced research record you can inspect and rerun. Your first scan is free, and this one starts with 3D-Bioprinted Vascularized Tissue Constructs already loaded, so edit it or scan as is.